BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kocher J, Yuan L. Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives. Future Virol 2015;10:899-913. [PMID: 26568768 DOI: 10.2217/fvl.15.57] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Ghosh S, Malik YS, Kobayashi N. Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future. Curr Drug Metab 2018;19:170-91. [PMID: 28901254 DOI: 10.2174/1389200218666170912161449] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
2 Galasiti Kankanamalage AC, Weerawarna PM, Rathnayake AD, Kim Y, Mehzabeen N, Battaile KP, Lovell S, Chang KO, Groutas WC. Putative structural rearrangements associated with the interaction of macrocyclic inhibitors with norovirus 3CL protease. Proteins 2019;87:579-87. [PMID: 30883881 DOI: 10.1002/prot.25682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29:695-747. [PMID: 27281742 DOI: 10.1128/cmr.00102-15] [Cited by in Crossref: 592] [Cited by in F6Publishing: 276] [Article Influence: 118.4] [Reference Citation Analysis]
4 Galasiti Kankanamalage AC, Kim Y, Rathnayake AD, Damalanka VC, Weerawarna PM, Doyle ST, Alsoudi AF, Dissanayake DMP, Lushington GH, Mehzabeen N, Battaile KP, Lovell S, Chang KO, Groutas WC. Structure-based exploration and exploitation of the S4 subsite of norovirus 3CL protease in the design of potent and permeable inhibitors. Eur J Med Chem 2017;126:502-16. [PMID: 27914364 DOI: 10.1016/j.ejmech.2016.11.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
5 Lindesmith LC, Mallory ML, Jones TA, Richardson C, Goodwin RR, Baehner F, Mendelman PM, Bargatze RF, Baric RS. Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination. J Infect Dis 2017;215:984-91. [PMID: 28453838 DOI: 10.1093/infdis/jix045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
6 Lei S, Samuel H, Twitchell E, Bui T, Ramesh A, Wen K, Weiss M, Li G, Yang X, Jiang X, Yuan L. Enterobacter cloacae inhibits human norovirus infectivity in gnotobiotic pigs. Sci Rep 2016;6:25017. [PMID: 27113278 DOI: 10.1038/srep25017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
7 Galasiti Kankanamalage AC, Kim Y, Rathnayake AD, Alliston KR, Butler MM, Cardinale SC, Bowlin TL, Groutas WC, Chang K. Design, Synthesis, and Evaluation of Novel Prodrugs of Transition State Inhibitors of Norovirus 3CL Protease. J Med Chem 2017;60:6239-48. [DOI: 10.1021/acs.jmedchem.7b00497] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
8 Lei S, Ryu J, Wen K, Twitchell E, Bui T, Ramesh A, Weiss M, Li G, Samuel H, Clark-Deener S, Jiang X, Lee K, Yuan L. Increased and prolonged human norovirus infection in RAG2/IL2RG deficient gnotobiotic pigs with severe combined immunodeficiency. Sci Rep 2016;6:25222. [PMID: 27118081 DOI: 10.1038/srep25222] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 9.4] [Reference Citation Analysis]
9 Prasad BV, Shanker S, Muhaxhiri Z, Deng L, Choi JM, Estes MK, Song Y, Palzkill T, Atmar RL. Antiviral targets of human noroviruses. Curr Opin Virol 2016;18:117-25. [PMID: 27318434 DOI: 10.1016/j.coviro.2016.06.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
10 Rathnayake AD, Kim Y, Dampalla CS, Nguyen HN, Jesri AM, Kashipathy MM, Lushington GH, Battaile KP, Lovell S, Chang KO, Groutas WC. Structure-Guided Optimization of Dipeptidyl Inhibitors of Norovirus 3CL Protease. J Med Chem 2020;63:11945-63. [PMID: 32945669 DOI: 10.1021/acs.jmedchem.0c01252] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Netzler NE, Enosi Tuipulotu D, White PA. Norovirus antivirals: Where are we now? Med Res Rev 2019;39:860-86. [PMID: 30584800 DOI: 10.1002/med.21545] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
12 Damalanka VC, Kim Y, Galasiti Kankanamalage AC, Rathnayake AD, Mehzabeen N, Battaile KP, Lovell S, Nguyen HN, Lushington GH, Chang KO, Groutas WC. Structure-guided design, synthesis and evaluation of oxazolidinone-based inhibitors of norovirus 3CL protease. Eur J Med Chem 2018;143:881-90. [PMID: 29227928 DOI: 10.1016/j.ejmech.2017.12.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
13 Aggarwal S, Hassan E, Baldridge MT. Experimental Methods to Study the Pathogenesis of Human Enteric RNA Viruses. Viruses 2021;13:975. [PMID: 34070283 DOI: 10.3390/v13060975] [Reference Citation Analysis]
14 Lei S, Ramesh A, Twitchell E, Wen K, Bui T, Weiss M, Yang X, Kocher J, Li G, Giri-Rachman E, Trang NV, Jiang X, Ryan EP, Yuan L. High Protective Efficacy of Probiotics and Rice Bran against Human Norovirus Infection and Diarrhea in Gnotobiotic Pigs. Front Microbiol 2016;7:1699. [PMID: 27853451 DOI: 10.3389/fmicb.2016.01699] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
15 Schmidt MA, Groom HC, Naleway AL, Biggs C, Salas SB, Shioda K, Marsh Z, Donald JL, Hall AJ. A model for rapid, active surveillance for medically-attended acute gastroenteritis within an integrated health care delivery system. PLoS One 2018;13:e0201805. [PMID: 30075030 DOI: 10.1371/journal.pone.0201805] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Oliveira LM, Blawid R, Orílio AF, Andrade BYG, Souza ACA, Nagata T. Development of an infectious clone and replicon system of norovirus GII.4. J Virol Methods 2018;258:49-53. [PMID: 29800592 DOI: 10.1016/j.jviromet.2018.05.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
17 Suzuki Y, Doan YH, Kimura H, Shinomiya H, Shirabe K, Katayama K. Predicting genotype compositions in norovirus seasons in Japan. Microbiol Immunol 2016;60:418-26. [PMID: 27168450 DOI: 10.1111/1348-0421.12384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
18 Balakrishnan A, Mun AB. Ribavirin inhibits Chandipura virus replication in Vero cells. J Med Virol 2020. [PMID: 32543712 DOI: 10.1002/jmv.26184] [Reference Citation Analysis]
19 Hosmillo M, Chaudhry Y, Nayak K, Sorgeloos F, Koo BK, Merenda A, Lillestol R, Drumright L, Zilbauer M, Goodfellow I. Norovirus Replication in Human Intestinal Epithelial Cells Is Restricted by the Interferon-Induced JAK/STAT Signaling Pathway and RNA Polymerase II-Mediated Transcriptional Responses. mBio 2020;11:e00215-20. [PMID: 32184238 DOI: 10.1128/mBio.00215-20] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 26.0] [Reference Citation Analysis]
20 Suzuki Y, Doan YH, Kimura H, Shinomiya H, Shirabe K, Katayama K. Predicting Directions of Changes in Genotype Proportions Between Norovirus Seasons in Japan. Front Microbiol 2019;10:116. [PMID: 30804908 DOI: 10.3389/fmicb.2019.00116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
21 Abo-zeid Y, Mantovani G, Irving WL, Garnett MC. Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: A possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles. Journal of Drug Delivery Science and Technology 2018;46:354-64. [DOI: 10.1016/j.jddst.2018.05.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
22 Damalanka VC, Kim Y, Galasiti Kankanamalage AC, Lushington GH, Mehzabeen N, Battaile KP, Lovell S, Chang KO, Groutas WC. Design, synthesis, and evaluation of a novel series of macrocyclic inhibitors of norovirus 3CL protease. Eur J Med Chem 2017;127:41-61. [PMID: 28038326 DOI: 10.1016/j.ejmech.2016.12.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
23 Ali ES, Rajapaksha H, Carr JM, Petrovsky N. Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens. Antiviral Res 2016;133:14-22. [PMID: 27421712 DOI: 10.1016/j.antiviral.2016.07.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]